Hormone · Investigational
Tabimorelin
No lawful US pathway
01 · Overview
Tabimorelin (NN703) is an orally active synthetic growth hormone secretagogue that acts as an agonist at the ghrelin receptor (GHS-R1a) to stimulate growth hormone release. Unlike injected peptide secretagogues, it was intended as an oral alternative to daily growth hormone injections (PMID 12610745).
A human study showed that tabimorelin inhibits the drug-metabolizing enzyme CYP3A4, substantially raising exposure to the co-administered drug midazolam (PMID 12610745).
02 · Research summary & key findings
In healthy men, seven days of oral tabimorelin produced dose-related growth hormone release and raised IGF-1 at higher doses, although the growth hormone response declined from day 1 to day 7 (PMID 11437473). In a randomized, placebo-controlled study of 97 adults with growth hormone deficiency, only 11 percent responded with a meaningful growth hormone peak and IGF-1 was unchanged after one week (PMID 12699438). The compound never reached approval, and no published trials have shown benefit on clinical outcomes such as frailty or function.
03 · Regulatory status
Tabimorelin is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Tabimorelin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Hormone
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for hormone optimization?
Tabimorelin is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on hormone optimization, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Oral
References
- [1]The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects Growth Horm IGF Res, 2001. PMID 11437473
- [2]A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate Eur J Clin Pharmacol, 2003. PMID 12610745
- [3]Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency Clin Endocrinol (Oxf), 2003. PMID 12699438
Primary literature
- PubMed: "Tabimorelin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Tabimorelin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Tabimorelin"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Hormone
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.